APA (7th ed.) Citation

Röllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., . . . Ehninger, G. (2015). Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial. The lancet. Oncology, 16(16), . https://doi.org/10.1016/S1470-2045(15)00362-9

Chicago Style (17th ed.) Citation

Röllig, Christoph, et al. "Addition of Sorafenib Versus Placebo to Standard Therapy in Patients Aged 60 Years or Younger with Newly Diagnosed Acute Myeloid Leukaemia (SORAML): A Multicentre, Phase 2, Randomised Controlled Trial." The Lancet. Oncology 16, no. 16 (2015). https://doi.org/10.1016/S1470-2045(15)00362-9.

MLA (9th ed.) Citation

Röllig, Christoph, et al. "Addition of Sorafenib Versus Placebo to Standard Therapy in Patients Aged 60 Years or Younger with Newly Diagnosed Acute Myeloid Leukaemia (SORAML): A Multicentre, Phase 2, Randomised Controlled Trial." The Lancet. Oncology, vol. 16, no. 16, 2015, https://doi.org/10.1016/S1470-2045(15)00362-9.